Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
21.33
Dollar change
+0.16
Percentage change
0.76
%
IndexRUT P/E- EPS (ttm)-2.08 Insider Own16.54% Shs Outstand74.35M Perf Week-0.09%
Market Cap1.62B Forward P/E- EPS next Y-2.40 Insider Trans-0.86% Shs Float63.54M Perf Month-0.23%
Income-152.63M PEG- EPS next Q-0.55 Inst Own90.30% Short Float16.22% Perf Quarter50.00%
Sales0.00M P/S- EPS this Y-10.26% Inst Trans4.45% Short Ratio7.04 Perf Half Y146.02%
Book/sh5.34 P/B3.99 EPS next Y-4.77% ROA-33.72% Short Interest10.30M Perf Year72.71%
Cash/sh5.57 P/C3.83 EPS next 5Y19.93% ROE-37.34% 52W Range7.41 - 24.17 Perf YTD48.33%
Dividend Est.- P/FCF- EPS past 5Y-3.94% ROI-36.96% 52W High-11.75% Beta0.85
Dividend TTM- Quick Ratio12.26 Sales past 5Y0.00% Gross Margin- 52W Low187.85% ATR (14)1.12
Dividend Ex-Date- Current Ratio12.26 EPS Y/Y TTM-2.75% Oper. Margin0.00% RSI (14)51.27 Volatility4.38% 5.33%
Employees142 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.21 Target Price30.25
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q-13.24% Payout- Rel Volume0.59 Prev Close21.17
Sales Surprise- EPS Surprise0.15% Sales Q/Q- EarningsFeb 27 AMC Avg Volume1.46M Price21.33
SMA20-2.11% SMA505.37% SMA20065.49% Trades Volume867,088 Change0.76%
Date Action Analyst Rating Change Price Target Change
Dec-22-23Initiated Mizuho Buy $26
Aug-11-23Initiated BofA Securities Buy $31
Jul-27-23Initiated Scotiabank Sector Perform $10.50
May-17-23Initiated BTIG Research Buy $31
Jan-31-23Initiated Stifel Buy $25
Jul-12-22Initiated Cantor Fitzgerald Overweight $30
Feb-15-22Initiated Jefferies Buy $35
May-05-21Resumed Credit Suisse Outperform $42
Apr-26-21Resumed Credit Suisse Outperform $42
Dec-07-20Reiterated H.C. Wainwright Buy $40 → $45
Mar-06-24 07:30AM
Mar-01-24 05:00PM
Feb-28-24 09:56AM
06:56AM
Feb-27-24 04:44PM
04:10PM Loading…
04:10PM
04:01PM
Feb-26-24 07:30AM
Feb-22-24 07:30AM
Feb-20-24 07:30AM
Feb-02-24 07:30AM
Feb-01-24 03:01PM
Jan-30-24 04:07PM
07:00AM
Jan-24-24 04:22PM
01:16PM Loading…
01:16PM
07:00AM
Dec-08-23 07:30AM
Nov-28-23 07:30AM
Nov-05-23 03:44PM
Nov-02-23 06:46PM
04:36PM
04:01PM
07:30AM
Oct-30-23 07:30AM
Oct-26-23 04:05PM
Oct-19-23 07:30AM
Oct-17-23 04:05PM
Oct-09-23 02:03AM
Oct-04-23 12:00PM
07:30AM Loading…
07:30AM
Sep-28-23 07:30AM
Sep-19-23 07:30AM
Aug-14-23 07:30AM
Aug-03-23 04:38PM
04:05PM
Jul-27-23 07:30AM
Jul-11-23 09:35AM
Jun-14-23 07:00AM
Jun-13-23 04:01PM
Jun-11-23 03:45AM
Jun-05-23 08:02PM
May-30-23 07:30AM
May-23-23 07:30AM
May-13-23 11:51AM
May-11-23 09:35AM
May-10-23 04:17PM
04:03PM
May-09-23 07:30AM
May-03-23 07:30AM
May-01-23 02:07PM
Apr-18-23 07:30AM
Apr-17-23 07:30AM
Mar-14-23 05:32PM
Mar-01-23 07:30AM
Feb-26-23 06:47AM
Feb-24-23 12:52PM
Feb-23-23 04:03PM
Feb-16-23 07:30AM
Feb-12-23 07:14AM
Feb-09-23 07:30AM
Feb-07-23 07:30AM
Jan-31-23 05:43PM
Jan-24-23 07:30AM
Jan-06-23 07:21AM
Dec-12-22 11:34AM
Dec-10-22 10:30AM
Dec-01-22 09:55AM
07:30AM
Nov-22-22 09:40AM
07:30AM
Nov-14-22 09:55AM
Nov-03-22 09:40AM
09:00AM
07:30AM
07:00AM
Nov-02-22 07:30AM
Oct-27-22 07:30AM
Oct-26-22 01:13PM
07:30AM
Oct-19-22 02:23PM
Sep-01-22 07:30AM
Aug-11-22 03:06PM
Aug-08-22 02:51PM
Aug-03-22 04:03PM
Aug-02-22 07:30AM
Jul-27-22 07:30AM
Jul-17-22 10:19AM
Jul-13-22 03:05PM
Jun-30-22 02:02PM
Jun-23-22 07:00AM
Jun-03-22 08:00AM
May-26-22 07:30AM
May-04-22 04:05PM
Apr-27-22 07:30AM
Apr-08-22 01:00PM
Mar-08-22 05:30PM
Feb-28-22 07:30AM
Feb-24-22 04:03PM
Feb-17-22 07:30AM
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DALE STEPHENChief Medical OfficerJan 30 '24Sale21.554,825103,98038,817Jan 31 05:30 PM
DALE STEPHENChief Medical OfficerJan 29 '24Sale17.807,158127,41643,642Jan 31 05:30 PM
DOYLE THOMAS JAMESSVP, Finance & AccountingJan 29 '24Sale17.802,31841,26248,093Jan 31 05:30 PM
Bair Teresa BrophyChief Legal OfficerJan 29 '24Sale17.802,05336,54468,979Jan 31 05:30 PM
FORD KATHLEENChief Operating OfficerJan 29 '24Sale17.801,49626,63021,602Jan 31 05:30 PM
WILSON TROY EDWARDPresident and CEOJan 24 '24Option Exercise6.0591,052550,59484,666Jan 26 05:10 PM
WILSON TROY EDWARDPresident and CEOJan 24 '24Sale20.2391,0521,841,982559Jan 26 05:10 PM
Malley ThomasDirectorJun 16 '23Buy11.5050,000575,000139,557Jun 21 04:29 PM